FDA Brief

Warning letters Drugs

FDA warning letter to

Natco Pharma Limited

High riskIssued Apr 8, 2024Posted Apr 16, 2024Center for Drug Evaluation and Research | CDER

FDA warned Natco Pharma of adulterated drugs after finding dirty equipment and weak investigations at an India plant.

What happened

FDA inspected Natco Pharma's Kothur Village, Telangana, India, drug manufacturing facility from October 9 to 18, 2023. Investigators found residue inside non-dedicated equipment labeled "cleaned," with multiple active drug ingredients above the company's allowable limit, and inadequate investigations into missing batch records and unexplained discrepancies. FDA also reviewed the company's November 8, 2023 response and found it inadequate.

What FDA found

  1. The company did not adequately clean non-dedicated equipment; equipment labeled "cleaned" had residues of multiple active drug ingredients above the company's limit, creating cross-contamination risk.

    21 CFR 211.67(a)
  2. The company did not thoroughly investigate batch discrepancies and record problems, including missing batch record pages, critical steps recorded 25 days after production, and a sample weight changed 22 days after analysis, without evidence-based root causes or corrective actions.

    21 CFR 211.192
  3. Employees handled and destroyed required manufacturing records in questionable ways, and the company's response lacked a full assessment of what records were destroyed.

What FDA wants

FDA asks Natco to provide an independent retrospective cleaning assessment, corrective and preventive action (CAPA) plans, and independent reviews of its investigations, records, and CAPA program, plus a report on all batches made for the U.S. market from January 2021 through 2023. The company must respond in writing within 15 working days and notify FDA before resuming U.S.-market drug production.

Who should pay attention

  • US patients and clinicians who rely on drugs made at this site
  • companies that buy, distribute, or rely on Natco Pharma products
  • quality teams at plants using non-dedicated equipment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium